id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7415 R21827 |
Miškov (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2016 | Spontaneous abortion | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.06 [0.30;13.97] C excluded (control group) |
2/13 3/37 | 5 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7043 R19885 |
Miškov (Carbamazepine) (Controls unexposed, disease free), 2016 | Spontaneous abortion | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
60.71 [2.73;1349.00] C excluded (control group) |
2/13 0/128 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7409 R21799 |
Miškov (Carbamazepine) (Controls unexposed, sick), 2016 | Spontaneous abortion | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.67 [0.06;43.79] C | 2/13 0/4 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6253 R16656 |
Arkilo (Carbamazepine), 2015 | Spontaneous miscarriages | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.69 [0.06;8.25] C | 1/17 2/24 | 3 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S333 R16613 |
Tomson (Carbamazepine), 2015 | Spontaneous abortions | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.01 [0.79;1.29] C | 130/1,713 144/1,910 | 274 | 1,713 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6290 R16967 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Spontaneous abortions | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.71 [0.49;1.03] C | 45/1,718 80/2,198 | 125 | 1,718 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5578 R14506 |
Diav-Citrin (Carbamazepine), 2001 | Miscarriages | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 0.80 [0.34;1.90] C | 8/108 19/210 | 27 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 0.90 [0.74;1.10] | 431 | 3,569 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine; 4: Carbamazepine) (Controls exposed to Lamotrigine, sick; 5: Carbamazepine;
Asymetry test p-value = 0.7540 (by Egger's regression)
slope=-0.0673 (0.1435); intercept=-0.2173 (0.6329); t=0.3433; p=0.7540
excluded 7415, 7043